A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.
Molecular subtypes of rare small bowel cancer now identify which patients face higher risk, guiding personalized treatment decisions.
This JNCI multi-institutional study developed and validated a hidden genome-based classifier for small bowel adenocarcinoma, identifying distinct molecular subtypes with differential survival outcomes, validated at MSK, MD Anderson, Stanford, Emory, and WUSM. The classifier addresses a critical gap in precision management of this rare GI malignancy with no existing molecular stratification framework.
What the study was
- Study design
- Multi-institutional retrospective cohort (genomic classifier development and validation)
- Population
- Small bowel adenocarcinoma patients across multiple major academic cancer centers
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Journal of the National Cancer Institute
Why it surfaced
JNCI multi-institutional study; first systematic molecular classification of SBA; high unmet need in rare tumor; strong multi-center validation design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.